USA flag logo/image

An Official Website of the United States Government

Improved Hypoglycemia Rescue Device

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
R44DK085809
Solicitation Year:
2011
Solicitation Topic Code:
NIDDK
Solicitation Number:
PA10-050
Small Business Information
XERIS PHARMACEUTICALS, INC.
3208 Red River Street Suite 300 Austin, TX 78705-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2011
Title: Improved Hypoglycemia Rescue Device
Agency: HHS
Contract: 2R44DK085809-02
Award Amount: $994,123.00
 

Abstract:

DESCRIPTION (provided by applicant): The objective of this project is to demonstrate the safety, pharmacokinetics and initial efficacy of a ready-to-use Glucagon Rescue Pen that will deliver a very low volume dose of a glucagon without reconstitution for hypoglycemic emergencies. To execute on this objective, it is necessary to first finalize the concentrated non-aqueous glucagon solution developed in the Phase 1 program and thereafter, manufacture cGMP clinical supplies of the glucagon pen for the Phase 1-2 trial. The final phase in this program will be to conduct a Phase 1-2 clinical trial that will study the safety, pharmacokinetics and preliminary efficacy of the Glucagon Rescue Pen. If successful, these experiments will demonstrate the safety and initial effectiveness of a simple, portable, glucagon delivery system to support an NDA-enabling Phase 3 (bioequivalency) study. The first Specific Aim of this proposed project is to optimize the non-aqueous glucagon formulation and produce cGMP clinical supplies in a pre-filled auto-injection pen. The second Specific Aim is to file IND documentation and get FDA approval for a Phase 1-2 clinical plan. The Third Specific Aim will be to conduct a Phase 1-2 clinical trial with the Glucagon Rescue Pen. Success Benchmarks will include: 1) rapid identification of non-aqueous glucagon formulation; 2) manufacture of GMP clinical supplies of the autoinjector pen that can proceed into long and accelerated stability testing and release for use in the clinical trial; 3) Fullenrollment of the Phase 1-2 clinical study that demonstrates the product's safety; pharmacokinetic profile (plasma glucagon levels) and a pharmacodynamic profile (blood glucose levels) that are equivalent to an aqueous-reconstituted glucagon. Meeting thesebenchmarks will justify advancing the product into an NDA-enabling bioequivalency study. PUBLIC HEALTH RELEVANCE: The current standard of care for hypoglycemic emergencies?the Glucagon Emergency Kit requires a diabetic's caregiver to reconstitutethe peptide powder contained in a vial using a 1 mL prefilled syringe and to assure complete solubilization prior to injection. A patient friendly, ready---to---use auto---injector Glucagon Pen will reduce caregiver and patient fear and risk, costs of 911calls and emergency room visits.

Principal Investigator:

John Kinzell
415-472-4623
jkinzell@xerispharma.com

Business Contact:

John Kinxell
415-472-4623
JKINZELL@XERISPHARMA.COM
Small Business Information at Submission:

XERIS PHARMACEUTICALS, INC.
3925 West Braker Lane, 3rd Floor Austin, TX 78759-5316

EIN/Tax ID: 120335242
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No